Research programme: orexin 1 receptor antagonist - AstraZeneca/Eolas
Latest Information Update: 03 Jul 2015
At a glance
- Originator Eolas Therapeutics
- Developer AstraZeneca
- Class Drug withdrawal therapies
- Mechanism of Action Orexin receptor type 1 antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Drug abuse; Neurological disorders; Smoking withdrawal